Primary mechanisms of action include: Enhanced insulin secretion : GLP-1 receptor agonists stimulate glucose-dependent insulin release from pancreatic beta cells, meaning insulin secretion increases when blood glucose is elevated but not when glucose levels are normal or low, reducing hypoglycemia risk Suppressed glucagon secretion : These medications inhibit glucagon release from pancreatic alpha cells, decreasing hepatic glucose production Delayed gastric emptying : GLP-1 receptor activation slows the rate at which food leaves the stomach, moderating postprandial glucose excursions Central appetite regulation : GLP-1 receptors in the brain, particularly in areas controlling satiety and food reward, are activated, leading to reduced appetite and caloric intake These combined effects result in improved glycemic control in patients with type 2 diabetes and significant weight loss in both diabetic and non-diabetic individuals

The rate of disintegration and dissolution depends on the supplement, how soluble it is, the ingredients, and more
Wegovy is the only FDA-approved brand of semaglutide indicated for weight loss
We performed a literature search using Google Scholar and PubMed with the keywords migraine, IIH, bariatric surgery, gastric banding, gastric sleeve, gastric bypass, weight loss medications, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), lipase inhibitors, and sympathomimetic amines
Treatment :3-6 sessions every 2 weeks Platelet-Rich Plasma (PRP) therapy utilizes the regenerative properties of platelets extracted from the patient's own blood